Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LPS vs GM-CSF Challenge Methodology in Healthy Volunteers
NCT03306589Phase 1Completed
- Sponsor
- GSK
- Start
- Aug 2017
- Primary completion
- Jan 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial comparing LPS Arm with GM-CSF Arm (2 arms). Primary endpoints: Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Tumor Necrosis Factor (TNF) Alpha at Day 3, Change From Baseline Primary Soluble Inflammatory Mediators in Blood: Interleukin (IL) 6 at Day 3 and 2 more. Started Aug 2017; status: completed.
02
Drugs
lipopolysaccharide endotoxinsargramostim
Beyond the preview
Go deeper on NCT03306589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03306589.